Scientific Presentations

Tolerability and Preliminary Efficacy of BXQ-350 for Solid Tumors and Gliomas: First-in-human, first-in-class phase 1 trial

Conflict of Interest Statement: Dr. Rixe holds a minor (<3%) equity interest in Bexion Pharmaceuticals, Inc.